Zavante acquisition doubles Nabriva chances of commercializing multiple drug-resistant antibiotics, says analyst

Ireland-incorporated Nabriva’s (Nasdaq: NBRV)recent acquisition of Zavante Therapeutics will see Zavante’s late-stage product Contepo (fosfomycin for injection) added to Nabriva’s pipeline of experimental drugs targeting multiple drug-resistant (MDR) bacteria.

Specialist antibiotics company Nabriva last month announced it had acquired USA-based Zavante for an upfront consideration of approximately 8.2 million of Nabriva ordinary shares (which includes an indemnity holdback) to Zavante Therapeutics’ former stockholders upon completion of the acquisition. In addition, Zavante’s former stockholders are eligible to receive up to $97.5 million upon the achievement of specified regulatory and commercial milestones,

Along with Nabriva’s own Phase III product lefamulin, Contepo gives Nabriva the rare opportunity to bring two first-in-class antibiotics to the US market in 2019, says data and analytics company GlobalData.